<DOC>
	<DOCNO>NCT03087786</DOCNO>
	<brief_summary>To study oral mucosal effect adult smoker associate use two Nicotine Lozenge formulation .</brief_summary>
	<brief_title>Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations</brief_title>
	<detailed_description>To assess oral mucosal health associate 3 week use test product , Nicotine Bitartrate 4 mg mint lozenge , relative reference product , Nicorette® [ Nicotine Polacrilex ] 4 mg mint lozenge , healthy adult smoker motivate quit smoking . To evaluate safety tolerability Nicotine Bitartrate 4 mg mint lozenge Nicorette® [ Nicotine Polacrilex ] 4 mg mint lozenge subject population .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Potential subject meet follow criterion Screening may include study . 1 . Sex Age : Males female age least 18 year old . 2 . Informed nature study agree able read , review , sign inform consent document prior commence study specific procedure . The informed consent document write English , therefore volunteer must ability read communicate English . 3 . Must smoke least 10 cigarette per day previous 12 month prior screen . 4 . Must smoke first cigarette within 30 minute wake . 5 . Must motivate quit smoking upon enrollment study . 6 . Contraception : Females childbearing potential , opinion Investigator , practice reliable method contraception least two month prior study participation must agree remain acceptable method contraception participate study period use study medication . Acceptable method contraception hormonal birth control , intrauterine device , double barrier method , vasectomize partner abstinence . 7 . Females childbearing potential require undergo serum ( Screening ) urine ( Day 0 ) pregnancy test ( must negative ) . 8 . Females nonchildbearing potential must surgically sterile least three month prior Screening postmenopausal least two year . 9 . General health : All study participant must good general health impairment would impede affect ability participate study deem acceptable Investigator . 10 . Compliance : All study participant must understand willing comply study procedure restriction . 11 . Consent : All study participant must demonstrate willingness participate evidence voluntary write informed consent must receive sign dated copy inform consent form . 1 . Females positive pregnancy test , pregnant , breastfeeding , intend become pregnant course study . 2 . Nicotine use : 1 . Is unable/unwilling stop use form tobacco ( e.g. , traditional cigarette , chew tobacco , nicotine gel , cigar , snuff tobacco , nicotine patch electronic cigarette ) duration study . 2 . Is unable/unwilling stop use nicotine replacement therapy product throughout duration study . 3 . Disease : Has medical history , opinion investigator , would jeopardize safety subject impact validity study result , e.g. , known history heart disease , recent myocardial infarction cerebrovascular accident ( i.e. , within 12 week prior enrollment ) , unstable angina , severe cardiac arrhythmia , diabetes peptic ulcer . 4 . Demonstrates reactive screen Hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 5 . Oral condition : 1 . Has history oral surgery ( include extraction ) within four week screen , operative dental work within seven day screen , presence clinically significant oral pathology ( determined oral health professional dentist dental hygienist ) include lesion , sore inflammation mouth would interfere study assessment confound result . 2 . Has fix retainer , orthodontic appliance , either maxillary and/or mandibular denture appliance may interfere placement product . 3 . Has current recurrent disease could affect site application , action , absorption study treatment , clinical assessment . 4 . Has severe gingivitis , periodontitis rampant caries ( extensive dental decay , i.e. , big/deep cavity , many teeth ) , diagnosed oral health professional dentist dental hygienist . 5 . Has presence oral perioral ulceration include herpetic lesion screen ( subject lesion may reexamine subsequent appointment may able admit later date ulceration herpetic lesion heals ) Study Visit Day 0 . 6 . Has elective dentistry schedule study duration . 6 . Allergy/Intolerance : 1 . Has know suspect intolerance hypersensitivity study material ( closelyrelated compound ) state ingredient . 2 . Has know genetic deficiency inability metabolize aspartame phenylalanine diagnose phenylketonuria . 7 . Clinical Study Participation : 1 . Participation another clinical study receipt investigational drug within 30 day screen visit start study . 2 . Previous participation study . 8 . Substance abuse : 1 . Current recent ( within two year screen ) history drug alcohol abuse , misuse , physical psychological dependence . 2 . Demonstrates positive alcohol breath test . 3 . Demonstrates positive urine drug screen without disclosure correspond prescribe concomitant medication ( ) Screening Study Visit Day 0 . 9 . Urine glucose : ) Positive glucose urine screen . 10 . Personnel : 1 . Is employee Sponsor study site . 2 . Is member household another subject trial . 11 . Use counter ( OTC ) prescription ( Rx ) lozenges start study ( Day 0 onward ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>